PA
MDGL icon

Profund Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Profund Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.55M Buy
4,862
+705
+17% +$337K 0.09% 148
2025
Q4 		$2.42M Sell
4,157
-45
-1% -$23K 0.07% 176
2025
Q3 		$1.93M Sell
4,202
-988
-19% -$369K 0.06% 199
2025
Q2 		$1.57M Sell
5,190
-1,063
-17% -$317K 0.06% 221
2025
Q1 		$2.07M Sell
6,253
-231
-4% -$75.9K 0.09% 171
2024
Q4 		$2M Sell
6,484
-2,323
-26% -$653K 0.07% 184
2024
Q3 		$1.87M Buy
8,807
+1,991
+29% +$509K 0.07% 198
2024
Q2 		$1.91M Buy
6,816
+1,053
+18% +$251K 0.07% 185
2024
Q1 		$1.54M Sell
5,763
-1,397
-20% -$329K 0.06% 220
2023
Q4 		$1.66M Sell
7,160
-563
-7% -$98.5K 0.07% 212
2023
Q3 		$1.13M Buy
7,723
+1,898
+33% +$357K 0.06% 261
2023
Q2 		$1.35M Buy
5,825
+459
+9% +$124K 0.07% 244
2023
Q1 		$1.3M Buy
5,366
+4,233
+374% +$1.15M 0.08% 227
2022
Q4 		$329K Buy
+1,133
New +$111K 0.02% 592
2019
Q1 		– Sell
-1,829
Closed -$206K – 1225
2018
Q4 		$206K Buy
1,829
+67
+4% +$10.4K 0.01% 1014
2018
Q3 		$377K Buy
+1,762
New +$442K 0.01% 1026

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Profund Advisors's MDGL Position: Q1 2026 in Review

Profund Advisors increased its Madrigal Pharmaceuticals (MDGL) stake by 17% in Q1 2026, buying an estimated $337K and bringing the position to 4,862 shares worth $2.55M. The position accounts for 0.09% of the portfolio, ranked #148.

Profund Advisors first reported a position in MDGL in Q3 2018 and has held it in 16 quarters since. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Profund Advisors held 4,862 shares of Madrigal Pharmaceuticals worth $2.55M as of Q1 2026.
  • Profund Advisors bought 705 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $337K.
  • Madrigal Pharmaceuticals made up 0.09% of Profund Advisors's portfolio in Q1 2026, its #148 holding.
  • Profund Advisors first reported a position in Madrigal Pharmaceuticals in Q3 2018 and has held it in 16 quarters since.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.